Day: February 9, 2024

Shanghai, China, Feb. 09, 2024 (GLOBE NEWSWIRE) — Golden Sun Health Technology Group Limited, formerly known as Golden Sun Education Group Limited (the “Company” or “Golden Sun”) (Nasdaq: GSUN), a provider of tutorial services in China, today announced its strategic transition into the wellness industry in China. Since 2023, the Company has been endeavoring to establish its own wellness brands and an e-commerce platform that will be used to promote and sell wellness products, through a number of business initiatives. In August 2023, the Company established a subsidiary, Shanghai Jinheyu Biotechnology Co., Ltd., which has developed Fuding White Tea (福鼎白茶) brand white tea oral health products, including toothpaste, mouth freshening spray, and mouthwash. These products contain Fuding white tea (a specialty white tea produced in Fuding...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (the “Company” or “HYTN”) (CSE: HYTN) is pleased to announce a non-brokered private placement of up to 13,333,334 units of the Company (“Units”) at a price of $0.075 per Unit (the “Offering”), for aggregate gross proceeds of up to $1,000,000.05. Each Unit will be composed of one (1) common share in the capital of the Company (a “Share”) and one (1) common share purchase warrant of the Company (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one (1) additional Share (a “Warrant Share”) at a price of $0.25 per Warrant Share for a period of 24 months from the closing date of the Offering. The Company intends to use the net proceeds...

– BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a Humanitarian Aid Program to treat wartime trauma injuries in Ukraine – – The HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks – – PDUFA date set for August 10, 2024 – DURHAM, N.C., Feb. 09, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Humacyte’s Biologics License Application (BLA) seeking approval of the Human Acellular Vessel (HAV) in urgent arterial repair following extremity vascular trauma...

This news release constitutes a “Designated News Release” incorporated by reference in the prospectus supplement dated September 19, 2023 to Fortis’ short form base shelf prospectus dated November 21, 2022. ST. JOHN’S, Newfoundland and Labrador, Feb. 09, 2024 (GLOBE NEWSWIRE) — Fortis Inc. (“Fortis” or the “Corporation”) (TSX/NYSE: FTS), today filed its audited Consolidated Financial Statements, related Management Discussion and Analysis and Form 40-F for the year ended December 31, 2023, as well as its 2023 Annual Information Form, with Canadian securities regulatory authorities. The Corporation also filed its Form 40-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission. Copies of these documents are available electronically at www.sedarplus.ca (Canadian...